Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. HER2-low breast cancer really means that ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Before trastuzumab-deruxtecan, we didn't ...

Figure 2: Proposed treatment algorithm by HR status. Our proposed treatment algorithm reflects a potential treatment option for HR+, HER2 ultralow metastatic breast cancer based on the results of ...

Impact of the lymphovascular invasion on the prognosis in pT1-2N0 early breast cancer. Electronic patient reported outcomes in breast cancer patients receiving ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. I am delighted to ...

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration on Monday expanded ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...

Based on the DESTINY-Breast06 phase III trial results demonstrating statistically significant and clinically meaningful progression-free survival benefit in patients treated with Enhertu vs.

BOSTON--(BUSINESS WIRE)--Ibex Medical Analytics (Ibex), a leader in artificial intelligence (AI)-powered cancer diagnostics, today announced it has received In Vitro Diagnostic Medical Devices ...